{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:07:39Z","timestamp":1789578459611,"version":"build-2803163510"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160636"],"award-info":[{"award-number":["82160636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["YCSW2024409"],"award-info":[{"award-number":["YCSW2024409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the epidemic patterns of pretreatment drug resistance (PDR) and acquired drug resistance (ADR) in HIV-1 sequences from China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HIV-1 pol sequences and associated epidemiological data were collected from the Los Alamos HIV Sequence Database, NCBI, HIV Gene Sequence Database and PubMed. Genotypic resistance and subtypes were identified using the Stanford HIV Drug Resistance Database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 36\u200a263 sequences from ART-na\u00efve individuals and 1548 sequences from ART-experienced individuals with virological failure were evaluated. PDR prevalence was 6.64%, initially decreasing and then increasing to 7.84% (2018\u201322) due to NNRTI. Pooled ADR prevalence (44.96%) increased, with NNRTI and NRTI aligning with the overall trend. The percentage of multidrug resistance was more than that of single-drug resistance in PDR and especially ADR annually. PDR was most prevalent in Central China followed by Southwest and North. ADR prevalence was highest in North China followed by Northwest and Southwest. In ADR sequences, high-level resistance was more common, especially in NRTI. PDR sequences exhibited low-level or intermediate resistance, especially PI. Drug resistance mutations revealed distinct patterns in PDR and ADR. CRF01_AE, the predominant subtype in China, exhibited the highest proportions among most ART drugs and drug resistance mutations, with a few exceptions where CRF07_BC (prominent in the Northwest), CRF55_01B and CRF08_BC (prominent in the Southwest) showed the highest proportions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HIV-1 PDR and ADR prevalence in China exhibited diverse epidemiological characteristics, underscoring the importance of ongoing national monitoring of PDR, ADR and subtype; patient education on adherence; and personalized regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae260","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:54:27Z","timestamp":1721278467000},"page":"2575-2585","source":"Crossref","is-referenced-by-count":5,"title":["Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7585-4616","authenticated-orcid":false,"given":"Zhaoquan","family":"Wang","sequence":"first","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-8071","authenticated-orcid":false,"given":"He","family":"Jiang","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwu","family":"Pang","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-8803","authenticated-orcid":false,"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujia","family":"Liang","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejian","family":"Li","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Hou","sequence":"additional","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate School, Youjiang Medical University for Nationalities , Baise, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-5772","authenticated-orcid":false,"given":"Guanghua","family":"Lan","sequence":"additional","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine , Nanning, Guangxi ,","place":["China"]},{"name":"Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention , Nanning, Guangxi ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2024093023511438200_dkae260-B1","doi-asserted-by":"publisher","first-page":"846943","DOI":"10.3389\/fmicb.2022.846943","article-title":"Trends of transmitted and acquired drug resistance in Europe from 1981 to 2019: a comparison between the populations of late presenters and non-late presenters","volume":"13","author":"Miranda","year":"2022","journal-title":"Front Microbiol"},{"key":"2024093023511438200_dkae260-B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/infdis\/jiv008","article-title":"Interplay between transmitted and acquired HIV type 1 drug resistance: reasons for a disconnect","volume":"212","author":"De Luca","year":"2015","journal-title":"J Infect Dis"},{"key":"2024093023511438200_dkae260-B3","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S2352-3018(22)00059-5","article-title":"Drug resistance and use of long-acting ART","volume":"9","author":"da Silva","year":"2022","journal-title":"Lancet HIV"},{"key":"2024093023511438200_dkae260-B4","doi-asserted-by":"publisher","first-page":"e25656","DOI":"10.1002\/jia2.25656","article-title":"Prevalence of pretreatment HIV drug resistance in key populations: a systematic review and meta-analysis","volume":"23","author":"Macdonald","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2024093023511438200_dkae260-B5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.46234\/ccdcw2023.129","article-title":"Changes in HIV-1 subtypes\/sub-subtypes, and transmitted drug resistance among ART-na\u00efve HIV-infected individuals\u2014China, 2004\u20132022","volume":"5","author":"Liu","year":"2023","journal-title":"China CDC Wkly"},{"key":"2024093023511438200_dkae260-B6","author":"WHO"},{"key":"2024093023511438200_dkae260-B7","doi-asserted-by":"publisher","first-page":"100520","DOI":"10.1016\/j.ijmmb.2023.100520","article-title":"Delayed identification of treatment failure causes high levels of acquired drug resistance and less future drug options among HIV-1-infected South Indians","volume":"47","author":"Sivamalar","year":"2024","journal-title":"Indian J Med Microbiol"},{"key":"2024093023511438200_dkae260-B8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12981-021-00393-5","article-title":"Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa","volume":"18","author":"Chimukangara","year":"2021","journal-title":"AIDS Res Ther"},{"key":"2024093023511438200_dkae260-B9","doi-asserted-by":"publisher","first-page":"e25611","DOI":"10.1002\/jia2.25611","article-title":"HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates","volume":"23","author":"Rhee","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2024093023511438200_dkae260-B10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018","volume":"74","author":"McClung","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024093023511438200_dkae260-B11","doi-asserted-by":"publisher","first-page":"e25857","DOI":"10.1002\/jia2.25857","article-title":"The prevalence of pre-treatment and acquired HIV drug resistance in Vietnam: a nationally representative survey, 2017\u20132018","volume":"25","author":"Dat","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2024093023511438200_dkae260-B12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jclinepi.2022.02.005","article-title":"Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: systematic review and Bayesian evidence synthesis","volume":"148","author":"Hauser","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2024093023511438200_dkae260-B13","doi-asserted-by":"publisher","first-page":"e104474","DOI":"10.1371\/journal.pone.0104474","article-title":"Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany","volume":"9","author":"Schmidt","year":"2014","journal-title":"PLoS One"},{"key":"2024093023511438200_dkae260-B14","doi-asserted-by":"publisher","first-page":"101596","DOI":"10.1016\/j.bjid.2021.101596","article-title":"HIV-1 genetic diversity and drug resistance mutations in the northern Brazilian region","volume":"25","author":"Crispim","year":"2021","journal-title":"Braz J Infect Dis"},{"key":"2024093023511438200_dkae260-B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1089\/aid.2020.0194","article-title":"First assessment of acquired HIV-1 drug resistance and mutation patterns in Suriname","volume":"37","author":"Sno","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024093023511438200_dkae260-B16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/v14091992","article-title":"Molecular epidemiology and trends in HIV-1 transmitted drug resistance in Mozambique 1999\u20132018","volume":"14","author":"Ismael","year":"2022","journal-title":"Viruses"},{"key":"2024093023511438200_dkae260-B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/COH.0000000000000743","article-title":"Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence","volume":"17","author":"Bertagnolio","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2024093023511438200_dkae260-B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"2024093023511438200_dkae260-B19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jmv.27387","article-title":"Drug resistance pattern among ART-naive clients attending an HIV testing and counseling center in Dhaka, Bangladesh","volume":"94","author":"Rahman","year":"2022","journal-title":"J Med Virol"},{"key":"2024093023511438200_dkae260-B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12879-021-05794-5","article-title":"Increase in HIV-1-transmitted drug resistance among ART-na\u00efve youths at the China-Myanmar border during 2009\u20132017","volume":"21","author":"Ding","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024093023511438200_dkae260-B21","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00705-021-05140-9","article-title":"Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000\u20132016","volume":"166","author":"Yuan","year":"2021","journal-title":"Arch Virol"},{"key":"2024093023511438200_dkae260-B22","doi-asserted-by":"publisher","first-page":"2278254","DOI":"10.1080\/21505594.2023.2278254","article-title":"Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China","volume":"14","author":"Zhang","year":"2023","journal-title":"Virulence"},{"key":"2024093023511438200_dkae260-B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/jac\/dkab361","article-title":"High prevalence of HIV-1 transmitted drug resistance and factors associated with time to virological failure and viral suppression in Taiwan","volume":"77","author":"Huang","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024093023511438200_dkae260-B24","doi-asserted-by":"publisher","first-page":"860171","DOI":"10.3389\/fpubh.2022.860171","article-title":"Factors associated with newly HIV infection and transmitted drug resistance among men who have sex with men in Harbin, P. R. China","volume":"10","author":"Hui","year":"2022","journal-title":"Front Public Health"},{"key":"2024093023511438200_dkae260-B25","doi-asserted-by":"publisher","first-page":"1179568","DOI":"10.3389\/fpubh.2023.1179568","article-title":"Transmitted drug resistance and transmission clusters among ART-na\u00efve HIV-1-infected individuals from 2019 to 2021 in Nanjing, China","volume":"11","author":"Xu","year":"2023","journal-title":"Front Public Health"},{"key":"2024093023511438200_dkae260-B26","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1093\/jac\/dkac132","article-title":"Drug resistance and genetic transmission characteristics of HIV-1 CRF59_01B in infected patients in Guangdong Province, China","volume":"77","author":"Lan","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024093023511438200_dkae260-B27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12985-021-01653-6","article-title":"Transmitted drug resistance and transmission clusters among HIV-1 treatment-na\u00efve patients in Guangdong, China: a cross-sectional study","volume":"18","author":"Lan","year":"2021","journal-title":"Virol J"},{"key":"2024093023511438200_dkae260-B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jgar.2022.01.017","article-title":"Prevalence of transmitted drug resistance among ART-na\u00efve HIV-infected individuals, Beijing, 2015\u20132018","volume":"28","author":"Li","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2024093023511438200_dkae260-B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40249-023-01119-7","article-title":"Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysis","volume":"12","author":"Wu","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"2024093023511438200_dkae260-B30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/cid\/cix911","article-title":"The human immunodeficiency virus care continuum in China: 1985\u20132015","volume":"66","author":"Ma","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024093023511438200_dkae260-B31","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","article-title":"Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (20012017)","volume":"18","author":"Zuo","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2024093023511438200_dkae260-B32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12250-010-3122-4","article-title":"Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification","volume":"25","author":"Geng","year":"2010","journal-title":"Virol Sin"},{"key":"2024093023511438200_dkae260-B33","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of drug-resistant HIV-1 is stabilizing in Europe","volume":"200","author":"Vercauteren","year":"2009","journal-title":"J Infect Dis"},{"key":"2024093023511438200_dkae260-B34","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/jac\/dkad186","article-title":"Modelling the impact of treatment adherence on the transmission of HIV drug resistance","volume":"78","author":"Lai","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024093023511438200_dkae260-B35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/pathogens10030264","article-title":"HIV drug resistance mutations detection by next-generation sequencing during antiretroviral therapy interruption in China","volume":"10","author":"Li","year":"2021","journal-title":"Pathogens"},{"key":"2024093023511438200_dkae260-B36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/aid.2022.0077","article-title":"Prevalence of primary drug resistance among newly diagnosed HIV-1-infected individuals in Hunan Province, China","volume":"39","author":"Cao","year":"2023","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024093023511438200_dkae260-B37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1017\/S0950268817003016","article-title":"Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing","volume":"146","author":"Song","year":"2018","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"2024093023511438200_dkae260-B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/hiv.13252","article-title":"Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China","volume":"23","author":"Gao","year":"2022","journal-title":"HIV Med"},{"key":"2024093023511438200_dkae260-B39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1089\/aid.2021.0079","article-title":"High rate of HIV-1 drug resistance in antiretroviral therapy-failure patients in Liaoning Province, China","volume":"38","author":"Wei","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024093023511438200_dkae260-B40","doi-asserted-by":"publisher","first-page":"104257","DOI":"10.1016\/j.meegid.2020.104257","article-title":"HIV-1 genetic diversity and recombinant forms among men who have sex with men at a sentinel surveillance site in Xi'an City, China","volume":"81","author":"Chang","year":"2020","journal-title":"Infect Genet Evol"},{"key":"2024093023511438200_dkae260-B41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12879-022-07576-z","article-title":"Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2024093023511438200_dkae260-B42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12985-023-02112-0","article-title":"HIV-1 molecular transmission network and drug resistance in Chongqing, China, among men who have sex with men (2018\u20132021)","volume":"20","author":"Tan","year":"2023","journal-title":"Virol J"},{"key":"2024093023511438200_dkae260-B43","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2147\/DDDT.S406255","article-title":"Genetic diversity and characteristics of drug resistance among treatment-naive people living with HIV in Xi'an, China","volume":"17","author":"Xia","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"2024093023511438200_dkae260-B44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hiv.13253","article-title":"Pretreatment drug resistance in people living with HIV: a large retrospective cohort study in Chongqing, China","volume":"23","author":"Liu","year":"2022","journal-title":"HIV Med"},{"key":"2024093023511438200_dkae260-B45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/s12879-022-07734-3","article-title":"HIV-1 pretreatment drug resistance and genetic transmission network in the southwest border region of China","volume":"22","author":"Li","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2024093023511438200_dkae260-B46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12879-021-05854-w","article-title":"HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China","volume":"21","author":"Pang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024093023511438200_dkae260-B47","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jac\/dkae084","article-title":"Drug resistance and influencing factors in HIV-1-infected individuals under antiretroviral therapy in Guangxi, China","volume":"79","author":"Pang","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2024093023511438200_dkae260-B48","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/pathogens11111321","article-title":"Drug resistance to integrase strand-transfer inhibitors among HIV-1-infected adults in Guangdong, China","volume":"11","author":"Lan","year":"2022","journal-title":"Pathogens"},{"key":"2024093023511438200_dkae260-B49","doi-asserted-by":"publisher","first-page":"ofad016","DOI":"10.1093\/ofid\/ofad016","article-title":"Disparity of HIV-1 pretreatment drug resistance in men who have sex with men and the heterosexual population in Guangxi, China","volume":"10","author":"Pang","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024093023511438200_dkae260-B50","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jphs.2018.11.016","article-title":"Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy","volume":"139","author":"Luo","year":"2019","journal-title":"J Pharmacol Sci"},{"key":"2024093023511438200_dkae260-B51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/jac\/dkac016","article-title":"Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014\u201318","volume":"77","author":"Sun","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024093023511438200_dkae260-B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jgar.2023.01.002","article-title":"Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China","volume":"32","author":"Chen","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2024093023511438200_dkae260-B53","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1089\/aid.2023.0006","article-title":"Changes of viral load, drug resistance, and CD4 cell count in HIV-1-infected patients receiving antiretroviral therapy in Hebei Province, China, 2003\u20132019","volume":"39","author":"Lu","year":"2023","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024093023511438200_dkae260-B54","doi-asserted-by":"publisher","first-page":"919825","DOI":"10.3389\/fviro.2022.919825","article-title":"APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants","volume":"2","author":"Dwivedi","year":"2022","journal-title":"Front Virol"},{"key":"2024093023511438200_dkae260-B55","doi-asserted-by":"publisher","first-page":"1387720","DOI":"10.3389\/fmicb.2024.1387720","article-title":"Molecular genetic characterization analysis of a novel HIV-1 circulating recombinant form (CRF156_0755) in Guangdong, China","volume":"15","author":"Lin","year":"2024","journal-title":"Front Microbiol"},{"key":"2024093023511438200_dkae260-B56","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1017\/S095026882000093X","article-title":"The characteristics of pretreatment HIV-1 drug resistance in Western Yunnan, China","volume":"148","author":"Chen","year":"2020","journal-title":"Epidemiol Infect"},{"key":"2024093023511438200_dkae260-B57","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J Med Chem"},{"key":"2024093023511438200_dkae260-B58","doi-asserted-by":"publisher","first-page":"e32346","DOI":"10.1097\/MD.0000000000032346","article-title":"Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: a cross sectional study","volume":"101","author":"Omondi","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2024093023511438200_dkae260-B59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12981-022-00457-0","article-title":"Observational cohort study of rilpivirine (RPV) utilization in Europe","volume":"19","author":"Cozzi-Lepri","year":"2022","journal-title":"AIDS Res Ther"},{"key":"2024093023511438200_dkae260-B60","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4102\/sajhivmed.v20i1.949","article-title":"Switching at low HIV-1 RNA into fixed dose combinations: TDF\/FTC\/RPV is non-inferior to TDF\/FTC\/EFV in first-line suppressed patients living with HIV","volume":"20","author":"Munderi","year":"2019","journal-title":"South Afr J HIV Med"},{"key":"2024093023511438200_dkae260-B61","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/QAI.0000000000003027","article-title":"High levels of pretreatment HIV-1 drug resistance mutations among South African women who acquired HIV during a prospective study","volume":"91","author":"Beesham","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024093023511438200_dkae260-B62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12879-019-3871-0","article-title":"HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon","volume":"19","author":"Takou","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2024093023511438200_dkae260-B63","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1089\/aid.2016.0110","article-title":"Genotypic HIV-1 drug resistance among patients failing tenofovir-based first-line HAART in South India","volume":"32","author":"Dinesha","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024093023511438200_dkae260-B64","doi-asserted-by":"publisher","first-page":"569766","DOI":"10.3389\/fphar.2020.569766","article-title":"Antiretroviral long-term efficacy and resistance of lopinavir\/ritonavir plus lamivudine in HIV-1-infected treatment-na\u00efve patients (ALTERLL): 144-week results of a randomized, open-label, non-inferiority study from Guangdong, China","volume":"11","author":"Guo","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024093023511438200_dkae260-B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2023.07.013","article-title":"Patterns of HIV-1 drug resistance among HIV-infected patients receiving first-line antiretroviral therapy in Novosibirsk Region, Russia","volume":"35","author":"Kapustin","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2024093023511438200_dkae260-B66","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2024093023511438200_dkae260-B67","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14787210.2022.2081153","article-title":"Cabotegravir\/rilpivirine: the last FDA-approved drug to treat HIV","volume":"20","author":"Taki","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024093023511438200_dkae260-B68","doi-asserted-by":"publisher","first-page":"106627","DOI":"10.1016\/j.ijantimicag.2022.106627","article-title":"The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions","volume":"60","author":"Rusconi","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023511438200_dkae260-B69","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2575\/59460028\/dkae260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2575\/59460028\/dkae260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T23:51:19Z","timestamp":1727740279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/10\/2575\/7719016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":69,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae260","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,24]]}}}